Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
24 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
24 Apr 24
8-K
Departure of Directors or Certain Officers
18 Apr 24
8-K
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8 Apr 24
8-K
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
8-K
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
12 Mar 24
8-K
Kineta Announces Restructuring and Exploration of Strategic Alternatives
29 Feb 24
8-K
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
17 Jan 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
Entry into a Material Definitive Agreement
15 Dec 23
8-K
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
6 Nov 23
Registration and prospectus
424B3
Prospectus supplement
13 Nov 23
S-3
Shelf registration
3 Nov 23
D
$2.89 mm in options / securities to be acquired, 1 investor
20 Oct 23
424B5
Prospectus supplement for primary offering
5 Oct 23
424B3
Prospectus supplement
12 Jun 23
S-3
Shelf registration
1 Jun 23
424B5
Prospectus supplement for primary offering
21 Apr 23
424B5
Prospectus supplement for primary offering
20 Apr 23
POS AM
Prospectus update (post-effective amendment)
10 Feb 23
424B5
Prospectus supplement for primary offering
10 Feb 23
Proxies
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEFA14A
Additional proxy soliciting materials
5 Jun 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
DEFA14A
Additional proxy soliciting materials
13 May 19
Other
EFFECT
Notice of effectiveness
15 Nov 23
CORRESP
Correspondence with SEC
9 Nov 23
UPLOAD
Letter from SEC
9 Nov 23
EFFECT
Notice of effectiveness
13 Jun 23
CORRESP
Correspondence with SEC
8 Jun 23
UPLOAD
Letter from SEC
7 Jun 23
EFFECT
Notice of effectiveness
13 Feb 23
EFFECT
Notice of effectiveness
31 Jan 23
CORRESP
Correspondence with SEC
26 Jan 23
UPLOAD
Letter from SEC
25 Jan 23
Ownership
4
Shawn Iadonato
16 Apr 24
4
CRAIG W. PHILIPS
16 Apr 24
4
Keith Baker
16 Apr 24
4
Thierry Guillaudeux
16 Apr 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D/A
Iadonato Shawn
12 Feb 24
SC 13G/A
Magness Charles
12 Feb 24
4
Raymond J. Bartoszek
6 Dec 23
4
CRAIG W. PHILIPS
30 Nov 23
4
Shawn Iadonato
30 Nov 23